Data Presented for Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP Therapy Platform

April 14, 2026—RenovoRx, Inc., which is developing targeted oncology therapies and commercializing its FDA-cleared RenovoCath drug-delivery device, announced findings on the effectiveness of local, targeted intra-arterial chemotherapy administration using the company’s transarterial microperfusion therapy (TAMP) platform.

According to the company, the study assessed the potential application of metabolic imaging—fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT–in evaluating therapeutic outcomes after targeted intra-arterial drug delivery via TAMP in patients with refractory disease. The TAMP platform delivers chemotherapy directly near a tumor site. It helps to overcome the poor vascularity typical of solid tumors like locally advanced pancreatic cancer (LAPC), where intravenous chemotherapy is often less effective, noted RenovoRx.

The study abstract, “What PET/CT Reveals After Transarterial Microperfusion for Pancreatic Cancer,” was presented at the SIR 2026, the Society of Interventional Radiology’s annual scientific meeting, by a multidisciplinary team of experts, including Mustafa Al-Roubaie, MD. Dr. Al-Roubaie, an interventional radiologist at Moffitt Cancer Center in Tampa, Florida, is a member of RenovoRx’s Medical Advisory Board.

According to RenovoRx, the study concluded that TAMP is a promising approach for localized delivery of chemotherapeutic agents for the treatment of solid tumors such as LAPC, offering the potential for enhanced therapeutic drug delivery with reduced systemic toxicity. Metabolic imaging further demonstrated dramatic reductions in FDG avidity, suggesting treatment response even when tumor size changed minimally.

The company’s press release noted that eight cycles of intra-arterial chemotherapy were administered over 2 months, using the TAMP therapy platform enabled by the RenovoCath device. Post-treatment imaging results indicated that PET/CT may detect early treatment response before anatomical changes occur, stated RenovoRx.